These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia. Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219 [TBL] [Abstract][Full Text] [Related]
8. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia : A case report. Huemer F; Dejaco M; Grabmer C; Melchardt T; Neureiter D; Mayer G; Egle A; Greil R; Weiss L Wien Klin Wochenschr; 2017 Feb; 129(3-4):141-144. PubMed ID: 27878613 [TBL] [Abstract][Full Text] [Related]
9. Bevacizumab for treating Hereditary Hemorrhagic Telangiectasia patients with severe hepatic involvement or refractory anemia. Vázquez C; Gonzalez ML; Ferraris A; Bandi JC; Serra MM PLoS One; 2020; 15(2):e0228486. PubMed ID: 32032395 [TBL] [Abstract][Full Text] [Related]
10. Hereditary haemorrhagic telangiectasia: to transplant or not to transplant - is there a right time for liver transplantation? Muller YD; Oppliger R; Breguet R; Meyer P; Rubbia-Brandt L; Petignat PA; Harr T; Dayer E; Seebach JD Liver Int; 2016 Dec; 36(12):1735-1740. PubMed ID: 27864873 [TBL] [Abstract][Full Text] [Related]
11. An international, multicenter study of intravenous bevacizumab for bleeding in hereditary hemorrhagic telangiectasia: the InHIBIT-Bleed study. Al-Samkari H; Kasthuri RS; Parambil JG; Albitar HA; Almodallal YA; Vázquez C; Serra MM; Dupuis-Girod S; Wilsen CB; McWilliams JP; Fountain EH; Gossage JR; Weiss CR; Latif MA; Issachar A; Mei-Zahav M; Meek ME; Conrad M; Rodriguez-Lopez J; Kuter DJ; Iyer VN Haematologica; 2021 Aug; 106(8):2161-2169. PubMed ID: 32675221 [TBL] [Abstract][Full Text] [Related]
13. An international survey to evaluate systemic bevacizumab for chronic bleeding in hereditary haemorrhagic telangiectasia. Al-Samkari H; Albitar HA; Olitsky SE; Clancy MS; Iyer VN Haemophilia; 2020 Nov; 26(6):1038-1045. PubMed ID: 32432841 [TBL] [Abstract][Full Text] [Related]
14. Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia. Khoueir N; Borsik M; Camous D; Herman P; Verillaud B Laryngoscope; 2019 Oct; 129(10):2210-2215. PubMed ID: 31566760 [TBL] [Abstract][Full Text] [Related]
15. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients. Guilhem A; Fargeton AE; Simon AC; Duffau P; Harle JR; Lavigne C; Carette MF; Bletry O; Kaminsky P; Leguy V; Lerolle N; Roux D; Lambert M; Chinet T; Bonnet D; Dupuis-Girod S; Rivière S PLoS One; 2017; 12(11):e0188943. PubMed ID: 29190827 [TBL] [Abstract][Full Text] [Related]
16. Is bevacizumab effective for reducing epistaxis in hereditary hemorrhagic telangiectasia? Chin CJ Laryngoscope; 2017 Feb; 127(2):289-290. PubMed ID: 27796042 [No Abstract] [Full Text] [Related]
17. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia. Parambil JG; Woodard TD; Koc ON Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965 [TBL] [Abstract][Full Text] [Related]
18. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature. Arizmendez NP; Rudmik L; Poetker DM Int Forum Allergy Rhinol; 2015 Nov; 5(11):1042-7. PubMed ID: 26202958 [TBL] [Abstract][Full Text] [Related]
19. Worsening of nose bleeding heralds high cardiac output state in hereditary hemorrhagic telangiectasia. Khalid SK; Pershbacher J; Makan M; Barzilai B; Goodenberger D Am J Med; 2009 Aug; 122(8):779.e1-9. PubMed ID: 19635281 [TBL] [Abstract][Full Text] [Related]